A Phase 2 interventional study of ARO-AAT in Alpha 1-Antitrypsin Deficiency, sponsored by Arrowhead Pharmaceuticals. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-15.
Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom — 8 open to participants now, 11 under way, 3 of them phase 3. alpha 1-Antitrypsin Deficiency · United Kingdom.
Among the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2019, is one of 8 in phase 2, and was the 9th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →8 of the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom are open now. Recruiting first, the newest first:
Richmond Research Institute · Sites in United Kingdom
Ages 18+
Tessera Therapeutics, Inc. · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 18–70
AIRNA Corporation · Sites in United Kingdom, Australia, Georgia and 6 more countries
Ages 18–74
Takeda · Sites in United Kingdom, United States, Austria and 3 more countries
Ages 18+
Wave Life Sciences USA, Inc. · Sites in United Kingdom, Australia, Canada and 3 more countries
Ages 18–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 6
First in 2003; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 54 across the 25 interventional studies, 500 across the 3 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 28 have an industry lead sponsor. The 10 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 13 (54%) have results posted.
Arrowhead Pharmaceuticals has 5 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07924462Richmond Research InstituteChronic Respiratory Disease Participant Engagement Study | 2027-08-01 |
| NCT06405633Wave Life Sciences USA, Inc.A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the the safety and efficacy of the investigational product, fazirsiran (TAK-999, ARO-AAT), administered subcutaneously to patients with alpha-1 antitrypsin deficiency associated liver disease (AATD).
Participants will be enrolled to receive multiple subcutaneous injections of fazirsiran (TAK-999, ARO-AAT). All eligible participants will require a pre-dose biopsy completed as part of the study within the screening window. All participants will undergo an end of study (EOS) biopsy. Treated participants will be offered the opportunity to continue treatment in an open label extension during which they will undergo a final biopsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: additional inclusion/exclusion criteria may apply, per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary Study Period (6-12 months): 100 mg dose of subcutaneous ARO-AAT for a minimum of 3 doses, with 2 optional treatment extension periods. Treatment Extension I (12 months): 100 mg dose of subcutaneous AROAAT every 12 weeks (Q12W). Treatment Extension II (up to 24 Months): 100 mg dose of subcutaneous ARO-AAT Q12W.
Drug: ARO-AAT
Primary Study Period (6-12 months): 200 mg dose of subcutaneous ARO-AAT for a minimum of 3 doses, with 2 optional treatment extension periods. Treatment Extension I (12 months): 200 mg dose of subcutaneous AROAAT Q12W. Treatment Extension II (up to 24 Months): 200 mg dose of subcutaneous ARO-AAT Q12W.
Drug: ARO-AAT
Primary Study Period (6-12 months): 200 mg dose of subcutaneous ARO-AAT for a minimum of 5 doses, with optional treatment extension periods. Treatment Extension I (12 months): 200 mg dose of subcutaneous AROAAT Q12W. Treatment Extension II (up to 24 Months): 200 mg dose of subcutaneous ARO-AAT Q12W.
Drug: ARO-AAT
solution for subcutaneous injection
Also known as: Fazirsiran Injection, TAK-999
Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 24: Cohorts 1/1b
Time frame: Baseline, Week 24
Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 48: Cohort 2
Time frame: Baseline, Week 48
Percent Change From Baseline in Serum Z-AAT Over Time: Cohorts 1/1b
Time frame: Baseline, Weeks 2, 4, 6, 16, 24
Percent Change From Baseline in Serum Z-AAT Over Time: Cohort 2
Time frame: Baseline, Weeks 2, 4, 6, 16, 22, 28, 34, 40, 48
Alanine Aminotransferase (ALT) Values Over Time: Cohorts 1/1b
Time frame: Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 24
ALT Values Over Time: Cohort 2
Time frame: Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 22, Week 28, Week 34, Week 40, Week 48
Gamma Glutamyl Transferase (GGT) Values Over Time: Cohorts 1/1b
Time frame: Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 24
GGT Values Over Time: Cohort 2
Time frame: Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 22, Week 28, Week 34, Week 40, Week 48
Fibrosis-4 Index (FIB4) Score Values Over Time: Cohorts 1/1b
The FIB 4 score evaluates the degree of fibrosis in patients suspected of or already diagnosed with hepatic fibrosis. FIB-4 is calculated as (Age (years) \* aspartate aminotransferase) / (platelets \* √(ALT)). The result provided from the above equation is interpreted according to 2 cut off values: FIB 4 \<1.45 indicates absence of cirrhosis (with a negative predictive value of 90% for advanced fibrosis); FIB 4 between 1.45 - 3.25 are deemed inconclusive; FIB 4 \>3.25 indicates cirrhosis (with a positive predictive value of 65% for advanced fibrosis).
Time frame: Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 24
FIB4 Score Values Over Time: Cohort 2
The FIB 4 score evaluates the degree of fibrosis in patients suspected of or already diagnosed with hepatic fibrosis. FIB-4 is calculated as (Age (years) \* aspartate aminotransferase) / (platelets \* √(ALT)). The result provided from the above equation is interpreted according to 2 cut off values: FIB 4 \<1.45 indicates absence of cirrhosis (with a negative predictive value of 90% for advanced fibrosis); FIB 4 between 1.45 - 3.25 are deemed inconclusive; FIB 4 \>3.25 indicates cirrhosis (with a positive predictive value of 65% for advanced fibrosis).
Time frame: Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 22, Week 28, Week 28 + 1 day, Week 34, Week 40, Week 48
Aspartate Aminotransferase-to-platelet Ratio Index (APRI) Values Over Time: Cohorts 1/1b
The APRI suggests the level of hepatic fibrosis and possible liver disease. APRI is calculated as 100\*(aspartate aminotransferase/40) / platelets. Scores indicate the following: \< 0.5 = fibrosis is ruled out; 0.5 - 0.7 = associated with some kind of liver damage; 0.7 - 1 = significant fibrosis; \> 1 = associated with cirrhosis.
Time frame: Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 24
APRI Values Over Time: Cohort 2
The APRI suggests the level of hepatic fibrosis and possible liver disease. APRI is calculated as 100\*(aspartate aminotransferase/40) / platelets. Scores indicate the following: \< 0.5 = fibrosis is ruled out; 0.5 - 0.7 = associated with some kind of liver damage; 0.7 - 1 = significant fibrosis; \> 1 = associated with cirrhosis.
Time frame: Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 22, Week 28, Week 34, Week 40, Week 48
N-Terminal Type III Collagen Propeptide (PRO-C3) Values Over Time: Cohorts 1/1b
PRO-C3 may be a biomarker for the formation of fibrotic tissue in the liver. For serum, the normal range is 6.1 - 13.8 ng/mL (based on a study of human serum samples from healthy men and women). Due to ethnic, dietary and age variations, the reference limits given may not apply to all populations. A reduction in Pro-C3 over time may indicate a reduction in hepatic fibrogenesis.
Time frame: Baseline, Weeks 4, 16, 24
PRO-C3 Values Over Time: Cohort 2
PRO-C3 may be a biomarker for the formation of fibrotic tissue in the liver. For serum, the normal range is 6.1 - 13.8 ng/mL (based on a study of human serum samples from healthy men and women). Due to ethnic, dietary and age variations, the reference limits given may not apply to all populations. A reduction in Pro-C3 over time may indicate a reduction in hepatic fibrogenesis.
Time frame: Baseline, Weeks 4, 16, 28, 40, 48
FibroScan® Values Over Time: Cohorts 1/1b
FibroScan is a type of liver elastography. Normal results are usually between 2 and 7 kilopascals (kPa), with results higher than the normal range if liver disease is present. The highest possible result is 75 kPa.
Time frame: Baseline, Week 24
FibroScan® Values Over Time: Cohort 2
FibroScan is a type of liver elastography. Normal results are usually between 2 and 7 kilopascals (kPa), with results higher than the normal range if liver disease is present. The highest possible result is 75 kPa.
Time frame: Baseline, Week 24
Portal Inflammation Over Time: Cohorts 1/1b
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of portal inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
Time frame: Baseline, Week 24
Portal Inflammation Over Time: Cohort 2
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of portal inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
Time frame: Baseline, Week 48
Interface Hepatitis Over Time: Cohorts 1/1b
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of interface hepatitis, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
Time frame: Baseline, Week 24
Interface Hepatitis Over Time: Cohort 2
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of interface hepatitis, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
Time frame: Baseline, Week 48
Lobular Inflammation Over Time: Cohorts 1/1b
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of lobular inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
Time frame: Baseline, Week 24
Lobular Inflammation Over Time: Cohort 2
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of lobular inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
Time frame: Baseline, Week 48
Hepatocyte Cell Death Over Time: Cohorts 1/1b
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the liver biopsy parameter of hepatocyte cell death. Hepatocyte Cell Death Score: 0 = No acidophil bodies; 1 = Few acidophil bodies; 2 = Many acidophil. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
Time frame: Baseline, Week 24
Hepatocyte Cell Death Over Time: Cohort 2
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of hepatocyte cell death. Hepatocyte Cell Death Score: 0 = No acidophil bodies; 1 = Few acidophil bodies; 2 = Many acidophil. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
Time frame: Baseline, Week 48
Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) Fibrosis Stage Score Over Time: Cohorts 1/1b
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the METAVIR fibrosis stage score. The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis C. The stage represents the amount of fibrosis or scarring. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis. F0: no fibrosis F1: portal fibrosis without septa F2: portal fibrosis with few septa F3: numerous septa without cirrhosis F4: cirrhosis
Time frame: Baseline, Week 24
Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) Fibrosis Stage Score Over Time: Cohort 2
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the METAVIR fibrosis stage score. The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis C. The stage represents the amount of fibrosis or scarring. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis. F0: no fibrosis F1: portal fibrosis without septa F2: portal fibrosis with few septa F3: numerous septa without cirrhosis F4: cirrhosis
Time frame: Baseline, Week 48
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An Adverse Event (AE) is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. Serious Adverse Event (SAE) is an AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a medically important event or reaction. TEAEs are AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. Not related events include those reported as 'Not Related' to study drug. Related events include those reported as 'Possibly Related' or 'Probably Related' to study drug.
Time frame: From first dose of study drug up to a maximum duration of study follow-up of 202 weeks.
| Milestone | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 |
|---|---|---|---|
| Started | 4 | 4 | 8 |
| Completed | 4 | 4 | 8 |
| Not completed | 0 | 0 | 0 |
| Milestone | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 |
|---|---|---|---|
| Started | 4 | 4 | 7 |
| Completed | 4 | 4 | 7 |
| Not completed | 0 | 0 | 0 |
| Milestone | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 |
|---|---|---|---|
| Started | 4 | 4 | 7 |
| Completed | 4 | 4 | 4 |
| Not completed | 0 | 0 | 3 |
| Withdrew: Rolled over to another study | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| percent change | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| Total Liver Z-AAT | -83.07 ± 5.830 | -79.84 ± 10.519 |
| Insoluble Liver-ZAAT | -81.58 ± 6.947 | -12.91 ± 131.702 |
| Soluble Liver Z-AAT | -85.36 ± 4.835 | -88.18 ± 5.718 |
| percent change | ARO-AAT 200 mg Cohort 2 |
|---|---|
| Total Liver Z-AAT | -90.26 ± 9.029 |
| Insoluble Liver-ZAAT | -84.83 ± 19.920 |
| Soluble Liver Z-AAT | -92.64 ± 7.482 |
| percent change | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| Week 2 | -69.12 ± 12.381 | -77.28 ± 7.394 |
| Week 4 | -80.24 ± 8.880 | -88.07 ± 4.931 |
| Week 6 | -87.27 ± 6.140 | -91.79 ± 3.795 |
| Week 16 | -78.61 ± 9.186 | -83.08 ± 6.269 |
| Week 24 | -83.85 ± 5.426 | -89.47 ± 3.738 |
| percent change | ARO-AAT 200 mg Cohort 2 |
|---|---|
| Week 2 | -72.08 ± 8.645 |
| Week 4 | -82.22 ± 7.476 |
| Week 6 | -89.92 ± 4.024 |
| Week 16 | -85.76 ± 6.106 |
| Week 22 | -90.87 ± 4.246 |
| Week 28 | -85.06 ± 7.847 |
| Week 34 | -89.54 ± 5.434 |
| Week 40 | -84.12 ± 12.433 |
| Week 48 | -89.58 ± 5.419 |
| U/L | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| Baseline (Day 1) | 58.5 ± 41.36 | 87.8 ± 30.42 |
| Day 2 (24-48 hr post-dose) | 58.5 ± 42.68 | 88.3 ± 32.72 |
| Week 2 | 76.5 ± 55.24 | 99.8 ± 53.89 |
| Week 4 | 62.3 ± 35.77 | 106.5 ± 42.57 |
| Week 4 (24-48 hr post-dose) | 60.3 ± 33.97 | 99.0 ± 38.58 |
| Week 6 | 49.8 ± 25.16 | 77.0 ± 20.85 |
| Week 16 | 35.7 ± 8.50 | 49.8 ± 5.25 |
| Week 16 (24-48 hr post-dose) | 31.5 ± 8.85 | 42.7 ± 3.06 |
| Week 24 | 27.8 ± 9.29 | 39.5 ± 3.11 |
| U/L | ARO-AAT 200 mg Cohort 2 |
|---|---|
| Baseline (Day 1) | 62.1 ± 14.98 |
| Day 2 (24-48 hr post-dose) | 58.6 ± 15.59 |
| Week 2 | 61.9 ± 20.17 |
| Week 4 | 55.3 ± 14.09 |
| Week 4 (24-48 hr post-dose) | 53.0 ± 14.83 |
| Week 6 | 54.9 ± 9.79 |
| Week 16 | 39.6 ± 13.13 |
| Week 16 (24-48 hr post-dose) | 37.5 ± 11.61 |
| Week 22 | 41.0 ± 14.58 |
| Week 28 | 36.7 ± 15.76 |
| Week 34 | 39.4 ± 11.13 |
| Week 40 | 33.4 ± 10.08 |
| Week 48 | 34.5 ± 10.54 |
| U/L | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| Baseline (Day 1) | 70.8 ± 35.30 | 244.8 ± 355.68 |
| Day 2 (24-48 hr post-dose) | 70.5 ± 39.07 | 247.3 ± 358.01 |
| Week 2 | 66.0 ± 37.15 | 210.8 ± 304.4 |
| Week 4 | 73.0 ± 43.37 | 222.0 ± 334.85 |
| Week 4 (24-48 hr post-dose) | 70.0 ± 45.19 | 210.3 ± 312.0 |
| Week 6 | 64.0 ± 35.62 | 199.3 ± 292.28 |
| Week 16 | 48.0 ± 23.25 | 135.3 ± 190.31 |
| Week 16 (24-48 hr post-dose) | 48.0 ± 22.38 | 161.7 ± 212.17 |
| Week 24 | 52.3 ± 28.31 | 112.0 ± 156.92 |
| U/L | ARO-AAT 200 mg Cohort 2 |
|---|---|
| Baseline (Day 1) | 62.5 ± 31.09 |
| Day 2 (24-48 hr post-dose) | 62.1 ± 33.21 |
| Week 2 | 60.6 ± 33.14 |
| Week 4 | 59.1 ± 49.82 |
| Week 4 (24-48 hr post-dose) | 57.6 ± 46.91 |
| Week 6 | 58.0 ± 36.21 |
| Week 16 | 49.1 ± 36.84 |
| Week 16 (24-48 hr post-dose) | 48.3 ± 38.68 |
| Week 22 | 48.5 ± 34.85 |
| Week 28 | 44.5 ± 34.62 |
| Week 34 | 45.3 ± 31.37 |
| Week 40 | 45.3 ± 38.20 |
| Week 48 | 48.5 ± 45.05 |
The FIB 4 score evaluates the degree of fibrosis in patients suspected of or already diagnosed with hepatic fibrosis. FIB-4 is calculated as (Age (years) \* aspartate aminotransferase) / (platelets \* √(ALT)). The result provided from the above equation is interpreted according to 2 cut off values: FIB 4 \<1.45 indicates absence of cirrhosis (with a negative predictive value of 90% for advanced fibrosis); FIB 4 between 1.45 - 3.25 are deemed inconclusive; FIB 4 \>3.25 indicates cirrhosis (with a positive predictive value of 65% for advanced fibrosis).
| numerical score | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| Baseline (Day 1) | 1.425 ± 0.3613 | 1.583 ± 0.9085 |
| Day 2 (24-48 hr post-dose) | 1.353 ± 0.2699 | 1.618 ± 0.9668 |
| Week 2 | 1.580 ± 0.5806 | 1.900 ± 1.3056 |
| Week 4 | 1.260 ± 0.3840 | 1.750 ± 1.3273 |
| Week 4 (24-48 hr post-dose) | 1.333 ± 0.4194 | 1.760 ± 1.3867 |
| Week 6 | 1.355 ± 0.4612 | 2.013 ± 1.1073 |
| Week 16 | 1.257 ± 0.3326 | 1.605 ± 1.221 |
| Week 16 (24-48 hr post-dose) | 1.227 ± 0.2230 | 1.940 ± 1.6210 |
| Week 24 | 1.265 ± 0.3196 | 1.688 ± 1.2563 |
The FIB 4 score evaluates the degree of fibrosis in patients suspected of or already diagnosed with hepatic fibrosis. FIB-4 is calculated as (Age (years) \* aspartate aminotransferase) / (platelets \* √(ALT)). The result provided from the above equation is interpreted according to 2 cut off values: FIB 4 \<1.45 indicates absence of cirrhosis (with a negative predictive value of 90% for advanced fibrosis); FIB 4 between 1.45 - 3.25 are deemed inconclusive; FIB 4 \>3.25 indicates cirrhosis (with a positive predictive value of 65% for advanced fibrosis).
| numerical score | ARO-AAT 200 mg Cohort 2 |
|---|---|
| Baseline (Day 1) | 1.395 ± 0.6634 |
| Day 2 (24-48 hr post-dose) | 1.543 ± 0.8209 |
| Week 2 | 1.383 ± 0.6358 |
| Week 4 | 1.420 ± 0.7054 |
| Week 4 (24-48 hr post-dose) | 1.356 ± 0.6344 |
| Week 6 | 1.367 ± 0.6419 |
| Week 16 | 1.299 ± 0.5636 |
| Week 16 (24-48 hr post-dose) | 1.271 ± 0.6521 |
| Week 22 | 1.336 ± 0.6269 |
| Week 28 | 1.377 ± 0.7152 |
| Week 34 | 1.239 ± 0.7527 |
| Week 40 | 1.319 ± 0.5782 |
| Week 48 | 1.502 ± 0.7680 |
The APRI suggests the level of hepatic fibrosis and possible liver disease. APRI is calculated as 100\*(aspartate aminotransferase/40) / platelets. Scores indicate the following: \< 0.5 = fibrosis is ruled out; 0.5 - 0.7 = associated with some kind of liver damage; 0.7 - 1 = significant fibrosis; \> 1 = associated with cirrhosis.
| numerical score | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| Baseline (Day 1) | 0.485 ± 0.2249 | 0.745 ± 0.3877 |
| Day 2 (24-48 hr post-dose) | 0.463 ± 0.2133 | 0.753 ± 0.3923 |
| Week 2 | 0.633 ± 0.3349 | 0.910 ± 0.5231 |
| Week 4 | 0.463 ± 0.2185 | 0.810 ± 0.4031 |
| Week 4 (24-48 hr post-dose) | 0.468 ± 0.1921 | 0.785 ± 0.4171 |
| Week 6 | 0.433 ± 0.1688 | 0.918 ± 0.1834 |
| Week 16 | 0.343 ± 0.0404 | 0.555 ± 0.3008 |
| Week 16 (24-48 hr post-dose) | 0.330 ± 0.0700 | 0.603 ± 0.4203 |
| Week 24 | 0.310 ± 0.0970 | 0.513 ± 0.2892 |
The APRI suggests the level of hepatic fibrosis and possible liver disease. APRI is calculated as 100\*(aspartate aminotransferase/40) / platelets. Scores indicate the following: \< 0.5 = fibrosis is ruled out; 0.5 - 0.7 = associated with some kind of liver damage; 0.7 - 1 = significant fibrosis; \> 1 = associated with cirrhosis.
| numerical score | ARO-AAT 200 mg Cohort 2 |
|---|---|
| Baseline (Day 1) | 0.500 ± 0.2102 |
| Day 2 (24-48 hr post-dose) | 0.515 ± 0.2023 |
| Week 2 | 0.486 ± 0.1551 |
| Week 4 | 0.479 ± 0.2226 |
| Week 4 (24-48 hr post-dose) | 0.454 ± 0.2127 |
| Week 6 | 0.463 ± 0.1678 |
| Week 16 | 0.372 ± 0.1812 |
| Week 16 (24-48 hr post-dose) | 0.358 ± 0.2160 |
| Week 22 | 0.386 ± 0.2011 |
| Week 28 | 0.387 ± 0.2642 |
| Week 34 | 0.379 ± 0.2449 |
| Week 40 | 0.349 ± 0.1768 |
| Week 48 | 0.440 ± 0.2310 |
PRO-C3 may be a biomarker for the formation of fibrotic tissue in the liver. For serum, the normal range is 6.1 - 13.8 ng/mL (based on a study of human serum samples from healthy men and women). Due to ethnic, dietary and age variations, the reference limits given may not apply to all populations. A reduction in Pro-C3 over time may indicate a reduction in hepatic fibrogenesis.
| μg/L | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| Baseline | 16.78 ± 2.960 | 25.15 ± 9.310 |
| Week 4 | 16.90 ± 3.539 | 22.10 ± 7.202 |
| Week 16 | 15.60 ± 1.818 | 19.30 ± 0.245 |
| Week 24 | 18.08 ± 2.159 | 16.63 ± 1.621 |
PRO-C3 may be a biomarker for the formation of fibrotic tissue in the liver. For serum, the normal range is 6.1 - 13.8 ng/mL (based on a study of human serum samples from healthy men and women). Due to ethnic, dietary and age variations, the reference limits given may not apply to all populations. A reduction in Pro-C3 over time may indicate a reduction in hepatic fibrogenesis.
| μg/L | ARO-AAT 200 mg Cohort 2 |
|---|---|
| Baseline | 18.21 ± 3.002 |
| Week 4 | 15.81 ± 2.948 |
| Week 16 | 17.03 ± 2.463 |
| Week 28 | 14.31 ± 2.362 |
| Week 40 | 15.10 ± 2.989 |
| Week 48 | 17.09 ± 7.967 |
FibroScan is a type of liver elastography. Normal results are usually between 2 and 7 kilopascals (kPa), with results higher than the normal range if liver disease is present. The highest possible result is 75 kPa.
| kPa | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| Baseline | 7.28 ± 2.632 | 12.70 ± 6.988 |
| Week 24 | 7.30 ± 3.730 | 10.55 ± 5.802 |
FibroScan is a type of liver elastography. Normal results are usually between 2 and 7 kilopascals (kPa), with results higher than the normal range if liver disease is present. The highest possible result is 75 kPa.
| kPa | ARO-AAT 200 mg Cohort 2 |
|---|---|
| Baseline | 9.89 ± 3.205 |
| Week 48 | 8.67 ± 3.263 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of portal inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
| percentage of participants | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| ≥ 1-point improvement | 25.0 | 50.0 |
| no change | 50.0 | 50.0 |
| ≥ 1-point worsening | 25.0 | 0.0 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of portal inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
| percentage of participants | ARO-AAT 200 mg Cohort 2 |
|---|---|
| ≥ 1-point improvement | 12.5 |
| no change | 37.5 |
| ≥ 1-point worsening | 0.0 |
| Baseline score = 0 | 50.0 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of interface hepatitis, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
| percentage of participants | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| ≥ 1-point improvement | 50.0 | 0.0 |
| no change | 0.0 | 100.0 |
| ≥ 1-point worsening | 25.0 | 0.0 |
| Baseline score = 0 | 25.0 | 0.0 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of interface hepatitis, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
| percentage of participants | ARO-AAT 200 mg Cohort 2 |
|---|---|
| ≥ 1-point improvement | 25.0 |
| no change | 25.0 |
| ≥ 1-point worsening | 0.0 |
| Baseline score = 0 | 50.0 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of lobular inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
| percentage of participants | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| ≥ 1-point improvement | 0.0 | 0.0 |
| no change | 25.0 | 50.0 |
| ≥ 1-point worsening | 50.0 | 50.0 |
| Baseline score = 0 | 25.0 | 0.0 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of lobular inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
| percentage of participants | ARO-AAT 200 mg Cohort 2 |
|---|---|
| ≥ 1-point improvement | 0.0 |
| no change | 62.5 |
| ≥ 1-point worsening | 12.5 |
| Baseline score = 0 | 25.0 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the liver biopsy parameter of hepatocyte cell death. Hepatocyte Cell Death Score: 0 = No acidophil bodies; 1 = Few acidophil bodies; 2 = Many acidophil. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
| percentage of participants | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| ≥ 1-point improvement | 0.0 | 0.0 |
| no change | 25.0 | 0.0 |
| ≥ 1-point worsening | 25.0 | 25.0 |
| Baseline score = 0 | 50.0 | 75.0 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of hepatocyte cell death. Hepatocyte Cell Death Score: 0 = No acidophil bodies; 1 = Few acidophil bodies; 2 = Many acidophil. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.
| percentage of participants | ARO-AAT 200 mg Cohort 2 |
|---|---|
| ≥ 1-point improvement | 0.0 |
| no change | 62.5 |
| ≥ 1-point worsening | 0.0 |
| Baseline score = 0 | 37.5 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the METAVIR fibrosis stage score. The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis C. The stage represents the amount of fibrosis or scarring. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis. F0: no fibrosis F1: portal fibrosis without septa F2: portal fibrosis with few septa F3: numerous septa without cirrhosis F4: cirrhosis
| percentage of participants | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 |
|---|---|---|
| ≥ 1-point improvement | 0.0 | 50.0 |
| no change | 100.0 | 50.0 |
| ≥ 1-point worsening | 0.0 | 0.0 |
Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the METAVIR fibrosis stage score. The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis C. The stage represents the amount of fibrosis or scarring. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis. F0: no fibrosis F1: portal fibrosis without septa F2: portal fibrosis with few septa F3: numerous septa without cirrhosis F4: cirrhosis
| percentage of participants | ARO-AAT 200 mg Cohort 2 |
|---|---|
| ≥ 1-point improvement | 50.0 |
| no change | 12.5 |
| ≥ 1-point worsening | 25.0 |
| Baseline score = 0 | 12.5 |
An Adverse Event (AE) is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. Serious Adverse Event (SAE) is an AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a medically important event or reaction. TEAEs are AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. Not related events include those reported as 'Not Related' to study drug. Related events include those reported as 'Possibly Related' or 'Probably Related' to study drug.
| participants | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 |
|---|---|---|---|
| ≥ 1 TEAE | 4 | 4 | 8 |
| ≥ 1 Serious TEAE | 0 | 3 | 5 |
| TEAE Severity = Mild | 3 | 1 | 2 |
| TEAE Severity = Moderate | 1 | 3 | 4 |
| TEAE Severity = Severe | 0 | 0 | 2 |
| TEAE = Not Related to Study Drug (SD) | 1 | 2 | 3 |
| TEAE = Related to SD | 3 | 2 | 5 |
| TEAE Injection Site Reaction (ISR) Severity = Mild | 2 | 1 | 3 |
| TEAE ISR Severity = Moderate | 0 | 0 | 1 |
| TEAE ISR Severity = Severe | 0 | 0 | 0 |
| TEAE Leading to SD Discontinuation | 0 | 0 | 0 |
| TEAE Requiring Dose Interruption of SD | 0 | 1 | 3 |
| TEAE Leading to PRemature Withdrawal From Study | 0 | 0 | 0 |
| TEAE Causing Death | 0 | 0 | 0 |
Collected over For a maximum duration of study follow-up of 202 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARO-AAT 100 mg Cohort 1b | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| ARO-AAT 200 mg Cohort 1 | 0/4 (0%) | 4/4 (100%) | 4/4 (100%) |
| ARO-AAT 200 mg Cohort 2 | 0/8 (0%) | 5/8 (62.5%) | 8/8 (100%) |
| Event | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 |
|---|---|---|---|
| Procedural pneumothoraxInjury, poisoning and procedural complications | 0/4 | 1/4 | 0/8 |
| Atrial fibrillationCardiac disorders | 0/4 | 1/4 | 0/8 |
| Non-cardiac chest painGeneral disorders | 0/4 | 1/4 | 0/8 |
| Viral myocarditisInfections and infestations | 0/4 | 1/4 | 0/8 |
| Humerus fractureInjury, poisoning and procedural complications | 0/4 | 0/4 | 1/8 |
| SyncopeNervous system disorders | 0/4 | 0/4 | 1/8 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/4 | 0/4 | 1/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/4 | 1/8 |
| CholelithiasisHepatobiliary disorders | 0/4 | 0/4 | 1/8 |
| DiverticulitisInfections and infestations | 0/4 | 0/4 | 1/8 |
| Event | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/4 | 4/4 | 6/8 |
| COVID-19Infections and infestations | 3/4 | 3/4 | 4/8 |
| FatigueGeneral disorders | 2/4 | 0/4 | 1/8 |
| Blood creatine phosphokinase increasedInvestigations | 2/4 | 1/4 | 2/8 |
| DizzinessNervous system disorders | 2/4 | 0/4 | 1/8 |
| HeadacheNervous system disorders | 1/4 | 2/4 | 1/8 |
| SciaticaNervous system disorders | 2/4 | 0/4 | 1/8 |
| EczemaSkin and subcutaneous tissue disorders | 0/4 | 2/4 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/4 | 1/4 | 2/8 |
| Chest painGeneral disorders | 1/4 | 0/4 | 3/8 |
| Age, Continuous(years) | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 | Total |
|---|---|---|---|---|
| Mean | 54.8 ± 10.01 | 44.5 ± 17.00 | 54.6 ± 13.68 | 52.1 ± 14.92 |
| Sex: Female, Male(Participants) | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 | Total |
|---|---|---|---|---|
| Female | 1 | 0 | 1 | 2 |
| Male | 3 | 4 | 7 | 14 |
| Ethnicity (NIH/OMB)(Participants) | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 4 | 8 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 | Total |
|---|---|---|---|---|
| White | 4 | 4 | 8 | 16 |
| Insoluble Z-Alpha 1 Antitrypsin (Z-AAT)(nmol/g) | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 | Total |
|---|---|---|---|---|
| Mean | 35.9750 ± 16.51694 | 33.2750 ± 53.31019 | 37.4500 ± 27.73075 | 36.0375 ± 31.38345 |
| Soluble Z-AAT(nmol/g) | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 | Total |
|---|---|---|---|---|
| Mean | 26.3500 ± 5.18813 | 24.3000 ± 10.58899 | 23.3125 ± 7.59914 | 24.3188 ± 7.50984 |
| Total Z-AAT(nmol/g) | ARO-AAT 100 mg Cohort 1b | ARO-AAT 200 mg Cohort 1 | ARO-AAT 200 mg Cohort 2 | Total |
|---|---|---|---|---|
| Mean | 62.3250 ± 15.81210 | 57.5750 ± 59.65391 | 60.7625 ± 34.04199 | 60.3563 ± 36.13456 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Apr 2022, 29 months.
Results were first posted in Apr 2025, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fazirsiran
alpha 1-Antitrypsin Deficiency →